Cite
HARVARD Citation
Song, Y. et al. (2020). HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. Journal for immunotherapy of cancer. 8 (2), p. . [Online].